| Literature DB >> 32717865 |
Xavier Montané1, Oliwia Kowalczyk2,3, Belen Reig-Vano1, Anna Bajek4, Krzysztof Roszkowski5, Remigiusz Tomczyk6, Wojciech Pawliszak6, Marta Giamberini1, Agnieszka Mocek-Płóciniak7, Bartosz Tylkowski8.
Abstract
The development of anticancer therapies that involve natural drugs has undergone exponential growth in recent years. Among the natural compounds that produce beneficial effects on human health, polyphenols have shown potential therapeutic applications in cancer due to their protective functions in plants, their use as food additives, and their excellent antioxidant properties. The possibility of combining conventional drugs-which are usually more aggressive than natural compounds-with polyphenols offers very valuable advantages such as the building of more efficient anticancer therapies with less side effects on human health. This review shows a wide range of trials in which polyphenolic compounds play a crucial role as anticancer medicines alone or in combination with other drugs at different stages of cancer: cancer initiation, promotion, and growth or progression. Moreover, the future directions in applications of various polyphenols in cancer therapy are emphasized.Entities:
Keywords: anticancer therapy; antioxidants; cancer; dietary supplements; flavonoids; natural health products; phytochemicals; polyphenols
Year: 2020 PMID: 32717865 PMCID: PMC7435624 DOI: 10.3390/molecules25153342
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Classification of polyphenols and flavonoids. Examples of each subgroup with anticancer activity are mentioned.
Figure 2Number of peer-reviewed articles published in the last decades in the field of polyphenols in cancer therapy.
Figure 3General structure of flavonoids.
Figure 4Chemical structure of the major subclasses of flavonoids.
Figure 5Number of peer-reviewed articles published in the last decades in the field of flavonoids in cancer therapy.
Figure 6Molecular structure of flavone backbone.
Summary of various polyphenols, their chemical structures, and their anticancer effects.
| Polyphenol | Applications in Cancer Therapy | References |
|---|---|---|
| Resveratrol | DNA protection against reactive oxygen species (ROS), trap the hydroxyl and superoxide groups and the free radicals produced into the cells. | [ |
|
| ||
| Curcumin | Reduce the expression of survivin and promotes E-chaderin. Apoptosis of colon cancer cells. | [ |
|
| ||
| Arctigenin | Inhibition of surviving and inducible Nitric oxide synthases (iNOS) expression and activation of caspase-3 protein. Apoptosis of OVCAR3 and SKOV3 ovarian cancer cells. | [ |
|
| ||
| Magnolol | Induces apoptosis of colorectal cancer cells through extrinsic/intrinsic pathways and inhibits nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling through protein kinase C delta type (PKCδ) inactivation. | [ |
|
| ||
| Honokiol | Synergistic effects of honokiol and doxorubicin in breast cancer by suppressing the metastasis of carcinogenic cells and apoptosis induction. | [ |
|
| ||
| Apoptosis of HCT-15 colon cancer cells through ROS mitochondrial pathway. | [ | |
|
| ||
| Kaempferol | Induces the apoptosis and DNA damage in MDA-MB-231 breast cancer cells by the upregulation of H2A histone family member X (γH2AX), caspase 3, caspase 9, and the protein serine/threonine kinase (p-ATM). | [ |
|
| ||
| Quercetin | Synergistic effects of quercetin and curcumin: Inhibition of cancer cell proliferation by regulation of the Wnt/β-catenin signaling and apoptotic pathways. | [ |
|
| ||
| Apigenin | Promotes apoptosis of pancreatic cancer cells by increasing intracellular ROS. | [ |
|
| ||
| Luteolin | Synergistic effects of luteolin and oxaliplatin: stops the proliferation of gastric cancer cell. | [ |
|
| ||
| Naringenin | Apoptosis of breast cancer cells by the increase of the activity of caspase-3 and caspase-9. | [ |
|
| ||
| Hesperetin | Synergistic effects of hesperetin and cisplatin: Modulation of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathway in A549 lung cancer cells. Inhibition of the multidrug resistance protein 1 (MDR 1) protein. Increases cisplatin efficiency. | [ |
|
| ||
| EGCG | Upregulates the activity of transferrin receptor (TfR) and inhibits the activity of Ferritin-H protein via iron chelation activity in HT-29 colorectal cancer cells. | [ |
|
| ||
| (−)-Epicatechin | Increasing intracellular ROS and the activity of BCL2 associated agonist of cell death (Bad) and bcl-2-like protein 4 (Bax) proteins, which results in the apoptosis of MDA-MB-231 and Michigan Cancer Foundation-7 (MCF-7) breast cancer cells. | [ |
|
| ||
| Genistein | Apoptosis of HL-60 leukemia cancer cells via endoplasmatic reticulum stress and mitochondria-dependent pathways. | [ |
|
| ||
| Daidzein | Decreases the expression of the multidrug resistance-associated protein 1 (MRP1) protein in both MCF-7 and MDA-MB-231 breast cancer cells. | [ |
|
| ||
| Ellagic acid | Inhibits cyclin-dependent kinase 6 (CDK6) gene activity. Decreases tumor proliferation in breast cancer cells. | [ |
|
| ||
| Delphinidin | Increases the activity of caspase-3, -7, and -8, causing the death of LNCaP prostate cancer cells. Intensifies the roles of genes involved in cancer cell apoptosis. Reduces the activity of genes that dissuade killing cancer cells. | [ |
|
|